Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 186, Issue 3, Pages 490-498Publisher
WILEY
DOI: 10.1111/bjh.15932
Keywords
thrombotic thrombocytopenic purpura; cost savings; effectiveness; TTP; ADAMTS13; PLASMIC
Categories
Funding
- Luick Family Fund of the Massachusetts General Hospital
- National Heart, Lung, and Blood Institute [1K08 HL136840-01]
Ask authors/readers for more resources
The PLASMIC score is a recently described clinical scoring algorithm that rapidly assesses the probability of severe ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) deficiency among patients presenting with microangiopathic haemolytic anaemia. Using a large multi-institutional cohort, we explored whether an approach utilizing the PLASMIC score to risk-stratify patients with suspected immune thrombotic thrombocytopenic purpura (iTTP) could lead to significant cost savings. Our consortium consists of institutions with an unrestricted approach to ADAMTS13 testing (Group A) and those that require pre-approval by the transfusion medicine service (Group B). Institutions in Group A tested more patients than those in Group B (P < 0 center dot 001) but did not identify more cases of iTTP (P = 0 center dot 29) or have lower iTTP-related mortality (P = 0 center dot 84). Decision tree cost analysis showed that applying a PLASMIC score-based strategy to screen patients for ADAMTS13 testing in Group A would have reduced costs by approximately 27% over the 12-year period of our study compared to the current approach. Savings were primarily driven by a reduction in unnecessary therapeutic plasma exchanges, but lower utilization of ADAMTS13 testing and subspecialty consultations also contributed. Our data indicate that using the PLASMIC score to guide ADAMTS13 testing and the management of patients with suspected iTTP could be associated with significant cost savings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available